Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Amazon Natural (AZNT) -- Ignore unavailable to you. Want to Upgrade?

To: Graystone who wrote (6240)	9/18/1998 10:36:00 AM
From: bmart	Respond to of 26163

biz.yahoo.com Friday September 18, 9:27 am Eastern Time HEMISPHERX BIOPHARMA Reports Illegal Shorting Of Its Stock to Securities Regulators PHILADELPHIA, Sept. 18 /PRNewswire/ -- HEMISPHERX BIOPHARMA (Amex: HEB - news) reported today that it had uncovered illegal shorting in its stock which it has now reported to the various compliance divisions of American Stock Exchange, Nasdaq and SEC. According to the company, the illegal shorting was orchestrated in conjunction with a purposefully erroneous and misleading report appearing in the September 28, 1998 issue of Business Week which claimed that the company's lead drug for treatment of Chronic Fatigue Syndrome (CFS) was ''highly toxic and ineffective.'' The company stated that contrary to this assertion, their drug was receiving additional regulatory approvals for commercial sales on an ongoing basis and that, in all of its major current markets, patients in the United States, Canada, Belgium and Austria, were demonstrating no clinically significant side effects and, according to the independent clinicians at various Universities in the United States and Europe conducting the studies, substantial evidence of quantitative improvement was being regularly observed. William A. Carter, M.D., the company's Chairman, further noted that the Food and Drug Administration (''FDA'') in its official document to the Interagency Committee on Chronic Fatigue Syndrome as recently as May 1998, said committees consisting of the Social Security Administration, National Institutes of Health, Centers for Disease Control, and Health and Human Services, specifically mentioned only the company's drug as being made available at this time to severely ill patients. Furthermore, the FDA has recently authorized additional expansions of the treatment protocol and the confirmatory placebo controlled phase III test. Dr. Carter stated that the drug had been injected over 40,000 times without clinically significant side effects and that these results were readily available in more than 200 peer reviewed scientific papers and would be further confirmed by clinical data to be presented at international CFS scientific meetings in Boston, MA and Rome, Italy during October and November, 1998. The Company stated that it would actively work with the NASD's task force on illegal short selling, as well as other regulatory agencies, in order to prevent illegal and disruptive manipulation of its stock. The Company also indicated that it had officially contacted Business Week to inquire as to how factually incorrect information could he published by one of its staff in light of the readily available clinical data which outright rejects the allegations concerning the drug, which data was readily available from numerous public domain scientific sources. The Company stated that its stock had been selected for the illegal manipulations solely due to its outstanding quantitative performance over the last several months which was due to the company meeting a number of strategic business benchmarks with respect to its broad based antiviral treatment programs. Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of HEMISPHERX involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. SOURCE: Hemispherx Biopharma, Inc.

To: Graystone who wrote (6240)	9/18/1998 10:43:00 AM
From: bmart	Read Replies (2) \| Respond to of 26163

biz.yahoo.com Thursday September 17, 10:36 pm Eastern Time HemispheRx could see decline in stock - BW NEW YORK, Sept 17 (Reuters) - A number of short-sellers are betting that the potential of biotech company HemispheRx BioPharma to produce an effective treatment for Chronic Fatigue Syndrome has been overstated, according to one analyst in the September 28 edition of Business Week. Manuel Asensio, head of investment company Asensio & Co. told Business Week's Inside Wall Street column he is shorting the stock with a target price of zero. Asensio believes HemispheRx's ampligen chronic fatigue drug is neither safe nor effective. The company's Chief Executive William Carter told Business Week the drug's safety and effectiveness have been well established. Asensio also said the company's shares are subject to substantial dilution from as-yet-unexercised warrants, options, and convertible preferred stock. Asensio calculates that when exercised, they will boost the number of shares outstanding by more than 80 percent. A HempispheRx spokesperson confirmed his contention, Business Week said. Carter told the magazine that he doesn't believe there will be a substantial dilutive effect. Shares of HemispheRx closed at 9- Thursday, down 7/16. The stock's year high is 13-3/16.

To: Graystone who wrote (6240)	9/18/1998 12:09:00 PM
From: Hawkmoon	Read Replies (3) \| Respond to of 26163

Graystone, I wonder how much AZNT pays these S. American "indians" for exporting their product to the US?? I also wonder how much AZNT pays for these stone "birds" they import?? Then finally, I wonder how much of that money goes to the actual Indians that produce these products for export to AZNT?? If it is a fair price and this money goes to the native craftmen and harvesters, I have no problem. But is sure appears to me that AZNT imports what would appear to be low-cost commoties, sells them at a fair profit, that then enables them to import more low-cost commodities thus creating an active exchange of US currency transactions between Brazil and the US. Has anyone asked what the wholesale cost of these imported products are for AZNT? The only people that would have this information would be US Customs employees and import brokers. This information should be inputted by both the consigner and consignee into the Automated Commercial System operated by US Customs. Merely curious about some of the finer details of AZNT business operations, that's all. Regards, Ron